JP Morgan Chase’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-57,434
| Closed | -$230K | – | 7576 |
|
|
2025
Q2 | $230K | Buy |
57,434
+26,263
| +84% | +$65K | ﹤0.01% | 5168 |
|
|
2025
Q1 | $28.4K | Sell |
31,171
-97,701
| -76% | -$135K | ﹤0.01% | 6048 |
|
|
2024
Q4 | $357K | Buy |
128,872
+99,944
| +345% | +$380K | ﹤0.01% | 5211 |
|
|
2024
Q3 | $151K | Buy |
28,928
+6,851
| +31% | +$35.6K | ﹤0.01% | 5525 |
|
|
2024
Q2 | $98.5K | Sell |
22,077
-39,500
| -64% | -$192K | ﹤0.01% | 5523 |
|
|
2024
Q1 | $472K | Buy |
61,577
+27,241
| +79% | +$149K | ﹤0.01% | 4834 |
|
|
2023
Q4 | $146K | Buy |
34,336
+12,336
| +56% | +$43.8K | ﹤0.01% | 5555 |
|
|
2023
Q3 | $92.4K | Sell |
22,000
-4,305
| -16% | -$21.9K | ﹤0.01% | 5526 |
|
|
2023
Q2 | $147K | Buy |
26,305
+26,245
| +43,742% | +$155K | ﹤0.01% | 5268 |
|
|
2023
Q1 | $0 | Hold |
60
| – | – | ﹤0.01% | 6963 |
|
|
2022
Q4 | $0 | Hold |
60
| – | – | ﹤0.01% | 6770 |
|
|
2022
Q3 | $0 | Hold |
60
| – | – | ﹤0.01% | 6647 |
|
|
2022
Q2 | $0 | Sell |
60
-310,873
| -100% | -$1.35M | ﹤0.01% | 6667 |
|
|
2022
Q1 | $1.27M | Sell |
310,933
-13,454
| -4% | -$79.2K | ﹤0.01% | 4097 |
|
|
2021
Q4 | $2.21M | Sell |
324,387
-7,504
| -2% | -$64.8K | ﹤0.01% | 3785 |
|
|
2021
Q3 | $3.85M | Buy |
331,891
+315,232
| +1,892% | +$4.92M | ﹤0.01% | 3264 |
|
|
2021
Q2 | $284K | Sell |
16,659
-4,665
| -22% | -$81.2K | ﹤0.01% | 5048 |
|
|
2021
Q1 | $422K | Buy |
21,324
+17,488
| +456% | +$386K | ﹤0.01% | 4782 |
|
|
2020
Q4 | $79K | Buy |
3,836
+807
| +27% | +$19.2K | ﹤0.01% | 5055 |
|
|
2020
Q3 | $72K | Buy |
+3,029
| New | +$75.2K | ﹤0.01% | 4832 |
|
JP Morgan Chase's INZY Position: Q3 2025 in Review
JP Morgan Chase sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 57,434 shares — an estimated $230K sold.
JP Morgan Chase first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $3.85M in Q3 2021. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- JP Morgan Chase reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- JP Morgan Chase sold 57,434 Inozyme Pharma shares in Q3 2025, an estimated $230K.
- JP Morgan Chase first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- JP Morgan Chase's Inozyme Pharma position peaked at $3.85M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.